Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme

HealthTech approach

HealthTech approach

Showing 1 to 10 of 303

TitleReference numberPublishedLast updated
Advanced breast cancer: diagnosis and treatmentCG81
Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancerTA1169
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA1167
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy (terminated evaluation)TA1168
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1165
Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatmentTA1164
Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation)TA1163
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancerTA1158
Osimertinib for treating EGFR mutation-positive unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapyTA1156
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more lines of systemic treatmentTA1153

Results per page

  1. 10
  2. 25
  3. 50
  4. All